
## Selim Corbacioglu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7693809/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Loss of Interleukin-10 Signaling and Infantile Inflammatory Bowel Disease: Implications for Diagnosis and Therapy. Gastroenterology, 2012, 143, 347-355.	1.3	400
2	Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet, The, 2012, 379, 1301-1309.	13.7	324
3	Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplantation, 2021, 56, 1651-1664.	2.4	221
4	Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. Bone Marrow Transplantation, 2019, 54, 1525-1552.	2.4	218
5	The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. Bone Marrow Transplantation, 2020, 55, 2071-2076.	2.4	163
6	Risk Factors for Development of and Progression of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome. Biology of Blood and Marrow Transplantation, 2019, 25, 1271-1280.	2.0	116
7	One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. Haematologica, 2022, 107, 1045-1053.	3.5	87
8	The minimum required level of donor chimerism in hereditary hemophagocytic lymphohistiocytosis. Blood, 2016, 127, 3281-3290.	1.4	83
9	Childhood supratentorial ependymomas with <i>YAP1â€MAMLD1</i> fusion: an entity with characteristic clinical, radiological, cytogenetic and histopathological features. Brain Pathology, 2019, 29, 205-216.	4.1	75
10	Drug safety evaluation of defibrotide. Expert Opinion on Drug Safety, 2013, 12, 123-136.	2.4	72
11	Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group. Bone Marrow Transplantation, 2020, 55, 485-495.	2.4	61
12	Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS). Bone Marrow Transplantation, 2019, 54, 1951-1962.	2.4	57
13	Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement. Lancet Haematology,the, 2020, 7, e61-e72.	4.6	56
14	Risk factors and outcomes according to age at transplantation with an HLA-identical sibling for sickle cell disease. Haematologica, 2019, 104, e543-e546.	3.5	47
15	Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey. Bone Marrow Transplantation, 2022, 57, 742-752.	2.4	45
16	Second Hematopoietic Stem Cell Transplantation for Post-Transplantation Relapsed Acute Leukemia in Children: A Retrospective EBMT-PDWP Study. Biology of Blood and Marrow Transplantation, 2018, 24, 1629-1642.	2.0	44
17	Gonadal Function after Busulfan Compared with Treosulfan in Children and Adolescents Undergoing Allogeneic Hematopoietic Stem Cell Transplant. Biology of Blood and Marrow Transplantation, 2019, 25, 1786-1791.	2.0	42
18	Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?—A multicenter EBMT-PDWP study. Bone Marrow Transplantation, 2020, 55, 1540-1551.	2.4	42

#	Article	IF	CITATIONS
19	Haploidentical CD3 or α/β T-cell depleted HSCT in advanced stage sickle cell disease. Bone Marrow Transplantation, 2019, 54, 1859-1867.	2.4	39
20	Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Bone Marrow Transplantation, 2020, 55, 681-694.	2.4	39
21	Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent Î <sup>2</sup> -Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9-Modified CD34+ Hematopoietic Stem and Progenitor Cells. Blood, 2020, 136, 3-4.	1.4	34
22	Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. Nature Reviews Clinical Oncology, 2021, 18, 435-453.	27.6	31
23	Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations. Bone Marrow Transplantation, 2021, 56, 1493-1508.	2.4	27
24	Defibrotide for children and adults with hepatic veno-occlusive disease post hematopoietic cell transplantation. Expert Review of Gastroenterology and Hepatology, 2017, 11, 885-898.	3.0	25
25	Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan failure. International Journal of Hematologic Oncology, 2017, 6, 75-93.	1.6	24
26	Recurrence of Ewing sarcoma: Is detection by imaging followâ€up protocol associated with survival advantage?. Pediatric Blood and Cancer, 2018, 65, e27011.	1.5	22
27	Alternative donor hematopoietic stem cell transplantation for sickle cell disease in Europe. Hematology/ Oncology and Stem Cell Therapy, 2020, 13, 181-188.	0.9	22
28	Outcomes of Unmanipulated Haploidentical Transplantation Using Post-Transplant Cyclophosphamide (PT-Cy) in Pediatric Patients With Acute Lymphoblastic Leukemia. Transplantation and Cellular Therapy, 2021, 27, 424.e1-424.e9.	1.2	22
29	Unmistakable Morphology? Infantile Malignant Osteopetrosis Resembling Juvenile Myelomonocytic Leukemia in Infants. Journal of Pediatrics, 2015, 167, 486-488.	1.8	20
30	Incidence of Anicteric Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome and Outcomes with Defibrotide following Hematopoietic Cell Transplantation in Adult and Pediatric Patients. Biology of Blood and Marrow Transplantation, 2020, 26, 1342-1349.	2.0	19
31	The role of haematopoietic stem cell transplantation for sickle cell disease in the era of targeted disease-modifying therapies and gene editing. Lancet Haematology,the, 2020, 7, e902-e911.	4.6	18
32	A comprehensive DNA panel next generation sequencing approach supporting diagnostics and therapy prediction in neurooncology. Acta Neuropathologica Communications, 2020, 8, 124.	5.2	18
33	Extracorporeal membrane oxygenation in children receiving haematopoietic cell transplantation and immune effector cell therapy: an international and multidisciplinary consensus statement. The Lancet Child and Adolescent Health, 2022, 6, 116-128.	5.6	17
34	Clinical characteristics and outcome of 60 pediatric patients with malignant melanoma registered with the German Pediatric Rare Tumor Registry (STEP). Klinische Padiatrie, 2017, 229, 322-328.	0.6	16
35	The role of HLA matching in unrelated donor hematopoietic stem cell transplantation for sickle cell disease in Europe. Bone Marrow Transplantation, 2020, 55, 1946-1954.	2.4	14
36	Haploâ€identical or mismatched unrelated donor hematopoietic cell transplantation for <scp>Fanconi</scp> anemia: Results from the <scp>Severe Aplastic Anemia Working Party</scp> of the <scp>EBMT</scp> . American Journal of Hematology, 2021, 96, 571-579.	4.1	14

SELIM CORBACIOGLU

#	Article	IF	CITATIONS
37	Management of venoâ€occlusive disease: the multidisciplinary approach to care. European Journal of Haematology, 2017, 98, 322-329.	2.2	13
38	Busulfan–fludarabine- or treosulfan–fludarabine-based myeloablative conditioning for children with thalassemia major. Annals of Hematology, 2022, 101, 655-665.	1.8	13
39	Recommendations on hematopoietic stem cell transplantation for patients with Diamond–Blackfan anemia. On behalf of the Pediatric Diseases and Severe Aplastic Anemia Working Parties of the EBMT. Bone Marrow Transplantation, 2021, 56, 2956-2963.	2.4	9
40	Systematic Review/Meta-Analysis on Efficacy of Allogeneic Hematopoietic Cell Transplantation in Sickle Cell Disease: An International Effort on Behalf of the Pediatric Diseases Working Party of European Society for Blood and Marrow Transplantation and the Sickle Cell Transplantation Internation Internation and Cellular Therapy, 2021, 27, 167.e1-167.e12.	1.2	8
41	Underdiagnosed veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) as a major cause of multi-organ failure in acute leukemia transplant patients: an analysis from the EBMT Acute Leukemia Working Party. Bone Marrow Transplantation, 2021, 56, 917-927.	2.4	8
42	A Systematic Review and Meta-Analysis of Studies of Defibrotide Prophylaxis for Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome. Clinical Drug Investigation, 2022, 42, 465-476.	2.2	7
43	Veno-occlusive disease/sinusoidal obstruction syndrome in patients with prior gemtuzumab ozogamicin: literature analysis of survival after defibrotide treatment. Blood Cancer Journal, 2020, 10, 29.	6.2	6
44	Specialized Pediatric Palliative Care Services in Pediatric Hematopoietic Stem Cell Transplant Centers. Children, 2021, 8, 615.	1.5	5
45	Haematological malignancies following temozolomide treatment for paediatric high-grade glioma. European Journal of Cancer, 2017, 81, 1-8.	2.8	4
46	GSTM1 and GSTT1 double null genotypes determining cell fate and proliferation as potential risk factors of relapse in children with hematological malignancies after hematopoietic stem cell transplantation. Journal of Cancer Research and Clinical Oncology, 2021, , 1.	2.5	4
47	COVID-19 in Children Following Hematopoietic Cell Transplantation: A Multinational Study of the European Bone Marrow Transplantation Society (EBMT) and the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH). Blood, 2021, 138, 2866-2866.	1.4	4
48	ABO incompatibile graft management in pediatric transplantation. Bone Marrow Transplantation, 2021, 56, 84-90.	2.4	3
49	Impact Of Prophylaxis With Defibrotide On The Occurrence Of Acute GvHD In Allogeneic HSCT. Blood, 2013, 122, 4591-4591.	1.4	3
50	Haematopoietic stem cell transplantation for severe autoimmune diseases in children: A review of current literature, registry activity and future directions on behalf of the autoimmune diseases and paediatric diseases working parties of the European Society for Blood and Marrow Transplantation. British Journal of Haematology, 2022, 198, 24-45.	2.5	3
51	The coming of age of the pediatric EBMT criteria. Bone Marrow Transplantation, 2021, 56, 767-768.	2.4	1
52	Impact of the human leucocyte antigen (HLA)â€B leader peptide dimorphism and HLAâ€A expression on outcomes of stem cell transplantation for sickle cell disease. British Journal of Haematology, 2021, 195, e128-e131.	2.5	1
53	Can We Improve Our Diagnostic Accuracy with Ultrasonography in Hepatic Veno-Occlusive Disease?. Pediatric Hematology and Oncology, 2020, 37, 273-274.	0.8	0
54	Prospective Clinical Phase II Results on Treosulfan-Based Conditioning Treatment of 70 Paediatric Patients with Haematological Malignancies. Blood, 2018, 132, 3354-3354.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Heparanase wildtype is associated with a reduced incidence of transplant-associated systemic vasculopathies. Hematology/ Oncology and Stem Cell Therapy, 2021, , .	0.9	0
56	Transplantation for Congenital Sideroblastic Anaemia Is Feasible and Offers Outcomes Comparable to Other Transfusion Dependent Anaemias. a Joint Retrospective Study of the Paediatric Diseases and Severe Aplastic Anaemia Working Parties (PDWP/SAAWP) of EBMT. Blood, 2020, 136, 45-47.	1.4	0
57	Safe transfer of pediatric patients from hematopoietic stem cell transplant unit into the pediatric intensive care unit: views of nurses and physicians. Bone Marrow Transplantation, 2022, , .	2.4	0
58	HGG-49. Gliomatosis cerebri in children: A collaborative report from the European Society for Pediatric Oncology (SIOPE). Neuro-Oncology, 2022, 24, i72-i73.	1.2	0